Download PDFPDF

Original research
Intensified lipid-lowering treatment with alirocumab in patients with coronary heart disease
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Treatment with PCSK9-inhibitors - a questionable measure
    • Uffe Ravnskov, MD, PhD, independent researcher Not affiiated to any institution
    • Other Contributors:
      • Michel de Lorgeril, cardiologist and researcher
      • Malcolm Kendrick, General practitioner
      • David M. Diamond, Professor

    According to Steffens et al.,1 patients with cardiovascular disease (CVD) whose cholesterol is too high despite ongoing cholesterol-lowering treatment should be treated with the PCSK9-inhibitor alirocumab. They base their conclusion on twelve weeks of treating 244 middle-aged and elderly patients (half of whom had familial hypercholesterolemia), where the LDL-cholesterol (LDL-C) was lowered by around 50% without any serious side effects. A relevant question is whether or not such treatment provide clinic benefit.
    The optimal way to demonstrate the benefits of any drug is through the use of double-blinded placebo-controlled trials. More than 30 PCSK9-inhibitor-trials have now been published,2,3 and none of them has demonstrated a reduction in overall or CV mortality. Only three, which included 73 936 patients with CVD, were performed correctly.2 Although LDL-cholesterol was lowered by more than 50%, none of them achieved a statistically significant reduction in either total or CVD mortality. In the longest trial (the 2.8 year long ODYSSEY-trial), which included almost 19,000 statin-treated patients, total mortality was a little lower in the alirocumab-group (3.5% vs 4.1%),2 which means that to save one life per year, it is necessary to treat more than 550 patients at a cost of more than five million US dollars.
    That such a strong cholesterol-lowering is ineffective is not unexpected, because there is much evidence that CVD is not caused by elevated...

    Show More
    Conflict of Interest:
    None declared.